Joel Greenbowe

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig et al. · Cancer Discovery · 2015 · 796 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Douglas B. Johnson, Garrett M. Frampton, Matthew J. Rioth et al. · Cancer Immunology Research · 2016 · 493 citations · Full text

Medicine, Immunology, Oncology +17

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

Aatur D. Singhi, Ben George, Joel Greenbowe et al. · Gastroenterology · 2019 · 337 citations · Full text

Medicine, Genetics, Oncology +17

Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

Alexander Drilon, Lu Wang, Maria E. Arcila et al. · Clinical Cancer Research · 2015 · 272 citations · Full text

Medicine, Genetics, Oncology +17

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

David Fabrizio, Thomas J. George, Richard F. Dunne et al. · Journal of Gastrointestinal Oncology · 2018 · 271 citations · Full text

Medicine, Immunology, Oncology +17